Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-World Outcomes and Dosing Patterns of Ebglyss in Atopic Dermatitis
NCT07856134Phase 4Not yet recruiting
- Sponsor
- Forefront Dermatology
- Start
- Nov 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 4 trial of lebrikizumab in atopic dermatitis (AD), sponsored by Forefront Dermatology. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07856134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07856134.